- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
emflaza
Synonyms :
deflazacort
Class :
corticosteroid
Dosage Forms & Strengths
Tablet
6mg
18mg
30mg
36mg
Oral suspension
22.75mg/ml
0.9
mg/kg
Orally
every day
Tablet
Dosage Forms & Strengths
Tablet
6mg
18mg
30mg
36mg
Oral suspension
22.75mg/ml
0.9
mg/kg
Orally
every day
Tablet
may increase the immunosuppressive effect of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may enhance the serum concentrations of active metabolites
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may decrease the diagnostic effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may increase the neuromuscular adverse effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of corticosteroids
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
vaccinia immune globulin intravenous (Rx)
may decrease the therapeutic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serums when combined with deflazacort
may enhance the serum concentration
may decrease the anti-neoplastic effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the adverse effects of corticosteroids
may increase the anti-coagulant effect of corticosteroids
may enhance the serum concentration of CYP3A4 substrates
may decrease the diagnostic effect of corticosteroids
may decrease the therapeutic effect of corticosteroids
may increase the adverse effects of corticosteroids
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
deflazacort: they may diminish serum concentrations of CYP3A4 Inducers
deflazacort: they may diminish serum concentrations of CYP3A4 Inducers
nafcillin will decrease the effect of action of deflazacort by affecting enzyme CYP3A4 metabolism.
the effect of nivolumab decreases on interacting with deflazacort.
the effect of deflazacort is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of deflazacort
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may decrease the therapeutic effect of hyperglycemia agents
may diminish the absorption of corticosteroids
may increase the toxic effect of corticosteroids
may increase the toxic effect of corticosteroids
It may diminish the serum potassium levels when combined with sodium acid phosphate
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of adverse effects
may decrease the serum concentration of each other
Frequency defined:
>10%
Increase in weight
Upper respiratory tract infection
Pollakiuria
Cushingoid appearance
Increased appetite
Cough
1-10%
Hirsutism
Erythema
Irritability
Abdominal discomfort
Dyspepsia
Thirst
Nausea
Influenza
Urinary tract infection
Neck pain
Muscle spasms
Testicular pain
Hypoventilation
Alopecia
Dysuria
Dizziness
Irregular heart rate
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: deflazacort
Pronounced: de·flaza·cort
Why do we use deflazacort?
It is used to treat Duchenne muscular dystrophy
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
